



CONTACT:  
Tularik Inc.  
Andrew J. Perlman, M.D., Ph.D.  
Corinne Lyle  
650-825-7000

Burns McClellan  
Aline Schimmel (Investors)  
212-213-0006  
Sharon Encabo (Media)  
415-352-6262

## **Tularik Inc. Files Registration Statement for Public Offering of Common Stock**

South San Francisco, Calif. -- February 23, 2000 -- Tularik Inc. (Nasdaq: TLRK) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 5,000,000 shares of common stock, including 3,750,000 shares expected to be offered by Tularik and 1,250,000 shares expected to be offered by selling stockholders. The offering is being made through an underwriter group managed by Lehman Brothers Inc., J.P. Morgan & Co., Chase H & Q, Thomas Weisel Partners LLC and Warburg Dillon Read LLC.

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, hypercholesterolemia, bacterial diseases and a class of drug targets known as orphan nuclear receptors.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

- more -

Copies of the prospectus relating to the offering may be obtained from Lehman Brothers Inc., 3 World Financial Center, New York, New York 10285, (212) 526-7000; J.P. Morgan & Co., 60 Wall Street, New York, New York 10260, (212) 648-8612; Chase H & Q, One Bush Street, San Francisco, California 94104, (415) 439-3000; Thomas Weisel Partners LLC, One Montgomery Street, San Francisco, California 94101, (415) 364-2500; or Warburg Dillon Read LLC, 229 Park Avenue, New York, New York 10171, (212) 821-3000.

####